Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Cutera: Remains an attractive takeout target — Gabelli & Co. (21.00)Gabelli notes given recent consolidation in the laser dermatology market with Allergan's (<strong>AGN</strong>) announced acquisition of Zeltiq (<strong>ZLTQ</strong>) (at 6x 2017 rev) and Hologic's (<strong>HOLX</strong>) announced acquisition of Cynosure (<strong>CYNO</strong>) (at 3x 2017 rev) in the past two days, <strong>CUTR is one of the few remaining publicly traded laser dermatology cos.</strong> CUTR trades at less than 2x. They maintain Buy based on their 2017 PMV of $27 per share, as CUTR is growing sales faster than the market and believe CUTR is an attractive acquisition candidate.</td> </tr></table>"